New drugs spread faster than tests

Nitazenes, medetomidine, cychlorphine and other novel synthetic substances are appearing in rapid succession in the illicit drug supply. Rapid tests for these drugs exist and return results within minutes.

Tests work everywhere except hospitals

Law enforcement, medical examiners, employers, community organizations and the general public can use rapid drug tests. Physicians treating overdoses in emergency rooms cannot, even when minutes are essential.

“A test can be used to fire someone or support a criminal case, yet it remains unavailable to the physician in an emergency room trying to save that person's life, when minutes are essential.”

FDA rules create the divide

Many tests for emerging drugs are labeled for forensic use only. Clinical tests for living patients require FDA approval as a diagnostic tool and cannot legally be used by medical clinics that follow federal law.

Xylazine and medetomidine changed treatment

Starting in 2020, xylazine spread through the fentanyl supply. It does not respond to naloxone and causes necrotic skin wounds increasing sepsis risk. Medetomidine later overtook xylazine supplies with similar dangers.

Doctors work blind without bedside tests

There are no point-of-care tests for xylazine, medetomidine or cychlorphine. Clinicians follow information from law-enforcement seizures, public-health alerts and months-old fatality data rather than tests at the bedside.

FDA should fast-track emerging drug tests

The FDA should establish an expedited pathway for clinical tests when the CDC or Office of National Drug Control Policy identifies a substance of significant public-health concern. Federal agencies could fund independent validation.

Better data saves lives and warns early

Rapid drug screens at the bedside would help physicians make better treatment decisions. Better hospital data could become an early-warning system rather than a retrospective record of a crisis already underway.

“Emergency departments are on the front lines of the overdose crisis; they should have access to the most innovative testing tools at the bedside, when minutes can make a difference.”